189 related articles for article (PubMed ID: 35613022)
1. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy.
Liu YC; Kwon J; Fabiani E; Xiao Z; Liu YV; Follo MY; Liu J; Huang H; Gao C; Liu J; Falconi G; Valentini L; Gurnari C; Finelli C; Cocco L; Liu JH; Jones AI; Yang J; Yang H; Thoms JAI; Unnikrishnan A; Pimanda JE; Pan R; Bassal MA; Voso MT; Tenen DG; Chai L
N Engl J Med; 2022 May; 386(21):1998-2010. PubMed ID: 35613022
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.
Shuai X; Zhou D; Shen T; Wu Y; Zhang J; Wang X; Li Q
Cancer Genet Cytogenet; 2009 Oct; 194(2):119-24. PubMed ID: 19781444
[TBL] [Abstract][Full Text] [Related]
3. Pseudogene-mediated DNA demethylation leads to oncogene activation.
Kwon J; Liu YV; Gao C; Bassal MA; Jones AI; Yang J; Chen Z; Li Y; Yang H; Chen L; Di Ruscio A; Tay Y; Chai L; Tenen DG
Sci Adv; 2021 Oct; 7(40):eabg1695. PubMed ID: 34597139
[TBL] [Abstract][Full Text] [Related]
4. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial.
Garcia-Manero G; Roboz G; Walsh K; Kantarjian H; Ritchie E; Kropf P; O'Connell C; Tibes R; Lunin S; Rosenblat T; Yee K; Stock W; Griffiths E; Mace J; Podoltsev N; Berdeja J; Jabbour E; Issa JJ; Hao Y; Keer HN; Azab M; Savona MR
Lancet Haematol; 2019 Jun; 6(6):e317-e327. PubMed ID: 31060979
[TBL] [Abstract][Full Text] [Related]
5. Oncogene Up-Regulation after Hypomethylating Therapy.
Dekker TJA
N Engl J Med; 2022 Aug; 387(5):476. PubMed ID: 35921465
[No Abstract] [Full Text] [Related]
6. Oncogene Up-Regulation after Hypomethylating Therapy. Reply.
Voso MT; Tenen DG; Chai L
N Engl J Med; 2022 Aug; 387(5):476-477. PubMed ID: 35921466
[No Abstract] [Full Text] [Related]
7. Aberrant hypomethylation of SALL4 gene in patients with myelodysplastic syndrome.
Lin J; Qian J; Yao DM; Qian W; Yang J; Wang CZ; Chai HY; Ma JC; Deng ZQ; Li Y; Chen Q
Leuk Res; 2013 Jan; 37(1):71-5. PubMed ID: 23122807
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target.
Ueno S; Lu J; He J; Li A; Zhang X; Ritz J; Silberstein LE; Chai L
Exp Hematol; 2014 Apr; 42(4):307-316.e8. PubMed ID: 24463278
[TBL] [Abstract][Full Text] [Related]
9. Why methylation is not a marker predictive of response to hypomethylating agents.
Voso MT; Santini V; Fabiani E; Fianchi L; Criscuolo M; Falconi G; Guidi F; Hohaus S; Leone G
Haematologica; 2014 Apr; 99(4):613-9. PubMed ID: 24688109
[TBL] [Abstract][Full Text] [Related]
10. Role Of TP53 mutations in predicting the clinical efficacy of hypomethylating therapy in patients with myelodysplastic syndrome and related neoplasms: a systematic review and meta-analysis.
Cai L; Zhao X; Ai L; Wang H
Clin Exp Med; 2020 Aug; 20(3):361-371. PubMed ID: 32613269
[TBL] [Abstract][Full Text] [Related]
11. Stem cell factor SALL4, a potential prognostic marker for myelodysplastic syndromes.
Wang F; Guo Y; Chen Q; Yang Z; Ning N; Zhang Y; Xu Y; Xu X; Tong C; Chai L; Cui W
J Hematol Oncol; 2013 Sep; 6(1):73. PubMed ID: 24283704
[TBL] [Abstract][Full Text] [Related]
12. Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.
Wang H; Li Y; Lv N; Li Y; Wang L; Yu L
Ann Hematol; 2018 Nov; 97(11):2025-2038. PubMed ID: 30084010
[TBL] [Abstract][Full Text] [Related]
13. Immunological effects of hypomethylating agents.
Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the DNA methylation pathway predict clinical efficacy to hypomethylating agents in myelodysplastic syndromes: a meta-analysis.
Du M; Zhou F; Jin R; Hu Y; Mei H
Leuk Res; 2019 May; 80():11-18. PubMed ID: 30884372
[TBL] [Abstract][Full Text] [Related]
15. Leukemic survival factor SALL4 contributes to defective DNA damage repair.
Wang F; Gao C; Lu J; Tatetsu H; Williams DA; Müller LU; Cui W; Chai L
Oncogene; 2016 Nov; 35(47):6087-6095. PubMed ID: 27132514
[TBL] [Abstract][Full Text] [Related]
16. Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells.
Yang J; Chai L; Liu F; Fink LM; Lin P; Silberstein LE; Amin HM; Ward DC; Ma Y
Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10494-9. PubMed ID: 17557835
[TBL] [Abstract][Full Text] [Related]
17. Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy.
Yang J; Gao C; Liu M; Liu YC; Kwon J; Qi J; Tian X; Stein A; Liu YV; Kong NR; Wu Y; Yin S; Xi J; Chen Z; Kumari K; Wong H; Luo H; Silberstein LE; Thoms JAI; Unnikrishnan A; Pimanda JE; Tenen DG; Chai L
Cancer Res; 2021 Dec; 81(23):6018-6028. PubMed ID: 34593523
[TBL] [Abstract][Full Text] [Related]
18. TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.
Yun J; Ji YS; Jang GH; Lim SH; Kim SH; Kim CK; Bae SB; Won JH; Park SK
Curr Issues Mol Biol; 2021 Aug; 43(2):917-931. PubMed ID: 34449560
[TBL] [Abstract][Full Text] [Related]
19. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
20. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.
Ma Y; Cui W; Yang J; Qu J; Di C; Amin HM; Lai R; Ritz J; Krause DS; Chai L
Blood; 2006 Oct; 108(8):2726-35. PubMed ID: 16763212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
